Jazz wins reimbursement nod from NICE for cannabinoid med Epidyolex

It took nearly 18 months, but after authorizing Jazz Pharmaceuticals’ Epidyolex for seizures associated with tuberous sclerosis complex (TSC), the U.K. now will reimburse users of the cannabidiol product.